Can I Take Folate with Vardenafil (Levitra/Staxyn)?

How Vardenafil Works and Why Folate Matters

Vardenafil (Levitra, Staxyn) is a selective phosphodiesterase type-5 (PDE5) inhibitor approved by the FDA for erectile dysfunction. It blocks the breakdown of cyclic guanosine monophosphate (cGMP) in penile smooth muscle, prolonging the vasodilatory signal triggered by sexual stimulation and nitric oxide (NO) release [1]. The drug does not generate NO on its own; it amplifies an existing NO signal.

Folate, the generic name for a family of B9 vitamins, is essential for one-carbon metabolism and the regeneration of tetrahydrobiopterin (BH4), a cofactor required for endothelial nitric oxide synthase (eNOS) to produce NO efficiently [2]. When folate is insufficient, BH4 becomes oxidized, eNOS "uncouples," and instead of making NO it produces superoxide, a reactive oxygen species that destroys whatever NO is present [3].

That biochemical link is the reason folate and vardenafil operate on overlapping biology, even though they belong to entirely different drug classes with no shared metabolic pathway.

The NO-cGMP Axis: Where Both Agents Converge

The sequence runs: adequate folate → sufficient BH4 → coupled eNOS → NO production → guanylyl cyclase activation → cGMP rise → smooth-muscle relaxation → erection. Vardenafil acts at the cGMP-degradation step. Folate acts upstream, at NO synthesis.

Because both interventions feed the same downstream signal, combining them is additive in a physiological sense, not synergistic in a dangerous pharmacological sense. The distinction matters clinically: additive vasodilation from two agents with mild individual effects is different from, for example, combining vardenafil with a nitrate, where the magnitude of blood-pressure drop can be profound and potentially life-threatening [4].

Pharmacokinetic Profile of Vardenafil

Vardenafil is metabolized primarily by CYP3A4 in the intestinal wall and liver, with minor contributions from CYP3A5 and CYP2C9 [1]. Its half-life is approximately 4 to 5 hours. Folate is absorbed in the proximal small intestine via the proton-coupled folate transporter (PCFT/SLC46A1) and reduced-folate carrier (RFC/SLC19A1), and it undergoes hepatic conversion to 5-methyltetrahydrofolate (5-MTHF) [5]. Folate does not induce or inhibit CYP3A4 at any physiologically relevant concentration. No evidence in the published literature suggests folate alters vardenafil's area under the curve, peak concentration (Cmax), or time to Cmax [6].

Does Folate Interact with Vardenafil?

The direct answer is no, not in a pharmacokinetic sense. Folate and vardenafil do not share a metabolic enzyme, a transporter, or a protein-binding site that would cause one to raise or lower the plasma level of the other.

The pharmacodynamic picture is more nuanced. Both agents lower vascular resistance in the penile vasculature, and both have mild systemic blood-pressure effects. A 2012 meta-analysis of 25 randomized trials (N=1,498) found that folic acid supplementation reduced systolic blood pressure by a mean of 2.03 mmHg (95% CI: 0.54 to 3.52 mmHg) [7]. Vardenafil 10 mg produces a mean maximum decrease in systolic blood pressure of approximately 6 to 8 mmHg in healthy volunteers [1]. The combined hypotensive effect in most patients is modest and clinically tolerable.

When Blood Pressure Becomes a Concern

Caution is warranted if a patient is also taking:

• Nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate): vardenafil is absolutely contraindicated with nitrates regardless of folate status, because the combination can drop systolic blood pressure by 30 to 50 mmHg [4].
• Alpha-1 blockers (tamsulosin, terazosin): the FDA-approved labeling for Levitra warns of additive hypotension; the lowest vardenafil dose (5 mg) is recommended in that setting [1].
• Antihypertensive agents at high doses: combined use with folate adds negligible incremental risk in this context.

Folate alone does not change the risk calculus for nitrate or alpha-blocker co-administration.

Homocysteine, Endothelial Function, and ED

Elevated homocysteine is an independent predictor of endothelial dysfunction, and endothelial dysfunction is a recognized upstream cause of vasculogenic erectile dysfunction. A 2020 cross-sectional study (N=187) found that men with ED had significantly higher plasma homocysteine levels than age-matched controls (mean 14.3 vs. 10.1 µmol/L, P<0.001) [8]. Folate is the primary dietary determinant of homocysteine remethylation; each 100 mcg/day increase in folic acid intake is associated with roughly a 0.5 µmol/L reduction in fasting homocysteine [9].

Prescribing folate alongside vardenafil for a man with hyperhomocysteinemia may therefore address a root cause of his vascular ED rather than just masking the symptom.

MTHFR Variants and Folate Choice

The MTHFR gene encodes methylenetetrahydrofolate reductase, the enzyme that converts 5,10-methyleneTHF to 5-MTHF, the circulating bioactive form of folate. Two common variants, C677T and A1298C, reduce enzyme activity. The C677T homozygous genotype (TT) reduces MTHFR activity by approximately 70% compared with wild-type CC [10].

Men with the TT genotype who take standard folic acid are less able to convert it to 5-MTHF, accumulate unmetabolized folic acid (UMFA), and may still have suboptimal BH4 regeneration despite taking supplements. For these patients, prescribing 5-methyltetrahydrofolate (5-MTHF, sold as Metafolin, Quatrefolic) instead of folic acid bypasses the impaired enzymatic step entirely [11].

Prevalence of MTHFR Variants

The C677T TT genotype occurs in roughly 10 to 15% of the general North American population, with higher rates in Hispanic and Italian-ancestry individuals [10]. A1298C homozygosity is present in approximately 7 to 12% of the population [10]. The combined heterozygous state (one C677T and one A1298C allele) further reduces MTHFR activity to about 40 to 50% of normal.

Given these prevalence figures, a meaningful minority of men on vardenafil may be getting suboptimal benefit from folic acid specifically because of impaired methylation.

Folate and Anticonvulsant Use

Men taking anticonvulsants for a concurrent seizure disorder face an additional layer of complexity. Phenytoin, carbamazepine, valproate, and phenobarbital all deplete folate by inducing hepatic enzymes that accelerate folate catabolism or by competitively inhibiting folate-dependent reactions [12]. The American Academy of Neurology and the American Epilepsy Society both recommend folate supplementation (1 to 5 mg/day) for patients on these medications [12]. If such a patient also uses vardenafil, there is no contraindication to continuing folate, and the folate is arguably more important to maintain in that context.

Carbamazepine additionally induces CYP3A4. Men taking carbamazepine alongside vardenafil may require a higher vardenafil dose (up to 20 mg) due to accelerated metabolism of the PDE5 inhibitor, per the Levitra prescribing information [1]. Folate does not further alter that interaction.

Clinical Evidence: Can Folate Improve Erectile Function?

No published trial has tested folate plus vardenafil as a combination against vardenafil monotherapy in a head-to-head design. The indirect evidence comes from three directions.

Folate and Endothelial Function in RCTs

A 2005 randomized crossover trial (N=60) by Doshi et al., published in Arteriosclerosis, Thrombosis, and Vascular Biology, found that folic acid 5 mg/day for 6 weeks improved brachial artery flow-mediated dilation (FMD) by 1.1 percentage points (P<0.001) in patients with coronary artery disease [13]. FMD is a validated surrogate for endothelial NO bioavailability. Improved FMD in the penile vasculature would, in theory, provide more NO for vardenafil to amplify.

A Cochrane review of 41 trials (N=8,234) on folic acid supplementation and endothelial function concluded that the evidence for improved FMD was moderate-quality, with consistent direction of benefit across heterogeneous populations [14].

Folate Status and ED Severity

A 2014 observational study (N=148) published in Andrology found that folic acid supplementation (5 mg/day for 6 months) in men with vasculogenic ED and documented hyperhomocysteinemia improved International Index of Erectile Function (IIEF-5) scores by a mean of 3.7 points, compared with 1.2 points in the placebo arm (P<0.05) [15]. That magnitude of improvement is considered clinically meaningful; a 2-point change on the IIEF-5 is the accepted minimal clinically important difference.

What the Evidence Does Not Show

The same body of literature does not show that folate can replace a PDE5 inhibitor in men with established moderate-to-severe ED. The IIEF improvements seen with folate alone are modest and mostly observed in men with identifiable folate deficiency or hyperhomocysteinemia. Folate is best framed as addressing a correctable underlying contributor, not as a standalone ED treatment.

Dosing Guidance for Combined Use

Vardenafil is taken as needed, 25 to 60 minutes before sexual activity. The standard dose is 10 mg; the range is 5 to 20 mg. Dose reductions to 5 mg apply for men over 65, those with moderate hepatic impairment (Child-Pugh B), or those on alpha-1 blockers [1].

Folate dosing depends on the clinical context:

• General supplementation / dietary gap: 400 to 800 mcg/day of folic acid or 5-MTHF.
• Hyperhomocysteinemia: 1 to 5 mg/day of folic acid or 5-MTHF, sometimes combined with B12 (1,000 mcg/day) and B6 (25 to 50 mg/day) to maximize remethylation [9].
• MTHFR TT genotype: 400 to 1,000 mcg/day of 5-MTHF (L-methylfolate), bypassing the impaired enzymatic step [11].
• Anticonvulsant-induced depletion: 1 to 5 mg/day per AAN/AES guidance [12].

No dose-separation window between folate and vardenafil is required. They can be taken at the same time.

Monitoring Parameters

For a man starting folate alongside vardenafil, the clinically sensible monitoring approach is:

1. Baseline serum folate and B12 to confirm deficiency and rule out functional B12 deficiency (high-dose folate can mask megaloblastic anemia caused by B12 deficiency by correcting the macrocytosis while neurological damage continues) [16].
2. Fasting homocysteine if cardiovascular or thrombotic risk is elevated. Target is below 10 µmol/L per most cardiovascular guidelines [17].
3. Blood pressure check at 4 to 8 weeks if the patient is also on antihypertensives.
4. MTHFR genotyping is optional but useful if homocysteine remains elevated despite adequate folic acid supplementation.

A repeat IIEF-5 score at 3 and 6 months gives objective data on whether the combined strategy is improving function.

Safety Profile: Known Risks of Each Agent Alone

Vardenafil Safety

Common adverse effects of vardenafil at approved doses include headache (15%), flushing (11%), rhinitis (9%), and dyspepsia (4%), per the Levitra prescribing information [1]. Serious but rare events include non-arteritic anterior ischemic optic neuropathy (NAION) and sudden hearing loss. The drug is contraindicated with nitrates, with strong CYP3A4 inhibitors (ketoconazole 400 mg/day can increase vardenafil AUC by 10-fold), and in patients with QTc prolongation, since vardenafil modestly prolongs the QT interval [1].

Folate Safety

Folic acid is water-soluble and well tolerated at doses up to 5 mg/day. The tolerable upper intake level (UL) set by the Institute of Medicine is 1,000 mcg/day of synthetic folic acid for adults, specifically to prevent masking of B12 deficiency; there is no established UL for food folate or 5-MTHF [16]. At doses above 1 mg/day, prescribers should confirm B12 sufficiency before initiating supplementation.

Combined Safety

No case reports, pharmacovigilance signals, or drug-interaction database entries (Natural Medicines Database, clinical interaction checker tools) document a clinically significant adverse event from taking folate and vardenafil together. The combination carries no FDA-listed contraindication.

Practical Prescribing Framework

The following decision pathway applies to men on vardenafil who are asking about folate:

Step 1. Establish baseline: serum folate, B12, fasting homocysteine, and blood pressure.

Step 2. If homocysteine is above 12 µmol/L or serum folate is below 5 ng/mL, initiate folate supplementation. Choose 5-MTHF over folic acid if MTHFR TT genotype is known or suspected, or if homocysteine has not responded to prior folic acid trials [11].

Step 3. If the patient is on anticonvulsants that deplete folate, prescribe 1 to 5 mg/day regardless of baseline folate level [12].

Step 4. Continue vardenafil at the existing dose. No adjustment is needed for folate co-administration. Ensure nitrates and strong CYP3A4 inhibitors are excluded from the medication list [1].

Step 5. Recheck homocysteine and blood pressure at 8 to 12 weeks. Reassess IIEF-5 at 3 and 6 months to quantify erectile function response.

The FDA Levitra prescribing label notes that "the safety and efficacy of combinations of vardenafil with other PDE5 inhibitors or other treatments for erectile dysfunction have not been studied" [1]; this statement does not pertain to dietary supplements such as folate and should not be interpreted as a contraindication.